Patrick Mille, MD

Dr. Mille's research interests are centered on advancing treatment strategies for GU cancers. He has contributed to studies evaluating the efficacy of triplet therapy—combining androgen deprivation therapy (ADT), androgen receptor (AR)-targeted therapy, and chemotherapy—in metastatic castration-sensitive prostate cancer (mCSPC). Findings from pivotal trials such as PEACE1 and ARASENS have demonstrated improved overall survival in patients with high-volume disease, leading to triplet therapy becoming a new standard of care for select patients.

In addition to his work on triplet therapy, Dr. Mille has explored the use of metronomic cyclophosphamide in metastatic castrate-resistant prostate cancer (mCRPC), investigating its potential benefits and genomic correlates. He has also co-authored research on bispecific PSMA antibodies and CAR-T cell therapies, highlighting their promise in treating mCRPC and the challenges associated with their development.

His clinical focus encompasses advanced GU cancers, with an emphasis on integrating innovative therapies into patient care.

Medical School

Medical University of South Carolina, Charleston, NC - 2010

Residency

Thomas Jefferson University Hospital, Philadelphia PA

Fellowship

Medical Oncology, Thomas Jefferson University Hospital, Philadelphia PA